We advised the capital markets adviser on the de-SPAC transaction

Davis Polk advised the capital markets adviser in connection with the de-SPAC transaction between Allurion Technologies Inc. and Compute Health Acquisition Corp. Upon closing, Allurion became a publicly listed company, and its common stocks and warrants became listed on the New York Stock Exchange under the symbols “ALUR” and “ALUR WS,” respectively.

Allurion is a company dedicated to ending obesity. Allurion’s weight loss platform combines the Allurion Gastric Balloon (the world’s first and only swallowable, procedure-less gastric balloon for weight loss), the Allurion Virtual Care Suite including the Allurion mobile app for consumers, Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional.

Compute Health is a special purpose acquisition company (SPAC) that was focused on healthcare businesses that were already leveraging or had the potential to leverage computational power, with an emphasis on companies in the medical device space, including imaging and robotics.

The Davis Polk corporate team included partner Derek Dostal and associate Wenyi Xu. Partner Corey M. Goodman and associates Benjamin Helfgott and Betsy Johnson provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post